NASDAQ$ESTA
Establishment Labs Holdings Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Establishment Labs' financial performance remained stable compared to the previous year, with a focus on expense reduction and strategic portfolio expansion.
Establishment Labs reported third-quarter revenue of $22.8 million, comparable to the same period in 2019. The company reduced operating expenses by 23% and maintained a strong cash balance of $81.4 million. Full-year revenue guidance is projected to be $80 to $82 million.
- Worldwide sales reached $22.8 million, aligning with pre-announced expectations.
- Full-year 2020 revenue is anticipated to be in the range of $80 to $82 million.
- Operating expenses decreased by 23% compared to the third quarter of 2019.
- Cash reserves remained strong at $81.4 million as of September 30.
Headline financials
Revenue & EPS history
Establishment Labs · Revenue · Quarterly
$22.8M
Forward guidance
Establishment Labs anticipates continued market share gains through expansion in breast reconstruction and development of new product categories, supporting growth in the coming years while planning entry into the U.S. and China.
Tailwinds
- Expansion in breast reconstruction market.
- Development of new product categories like minimally invasive augmentation.
- Continued market share gains.
- Entry into the U.S. market planned.
- Entry into the China market planned.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+1.5%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+2.4%
Avg return
30 days after
56%
18 / 32 earnings
Positive
+22.5%
Q3 2025
Best reaction
-26.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -4.3% | +2.9% | |
| Q4 2025 | -1.9% | +5.0% | -20.1% | |
| Q3 2025 | +22.5% | +37.0% | +43.2% | |
| Q1 2025 | +4.9% | +5.1% | +14.2% | |
| Q4 2024 | +17.9% | +28.1% | +12.1% | |
| Q3 2024 | -5.2% | -13.2% | -10.0% | |
| Q2 2024 | +3.4% | +20.6% | +23.5% | |
| Q1 2024 | +5.4% | +4.2% | -10.8% | |
| Q4 2023 | +15.1% | +19.6% | +28.2% | |
| Q3 2023 | -26.0% | -36.1% | -31.7% | |
| Q2 2023 | -8.4% | -12.0% | -12.2% | |
| Q1 2023 | +1.8% | -1.6% | -1.9% | |
| Q4 2022 | +7.2% | +10.3% | +0.3% | |
| Q3 2022 | -7.7% | +11.1% | +27.1% | |
| Q2 2022 | -3.0% | +1.3% | -0.4% | |
| Q1 2022 | -10.5% | -10.1% | +2.3% | |
| Q4 2021 | +3.3% | +1.6% | +11.5% | |
| Q3 2021 | -10.6% | -14.3% | -15.2% | |
| Q2 2021 | +6.0% | -3.7% | -3.1% | |
| Q1 2021 | -0.6% | -1.8% | +8.9% | |
| Q4 2020 | +0.4% | -6.8% | +9.5% | |
| Q3 2020 | +8.9% | -0.4% | +22.6% | |
| Q2 2020 | +6.2% | +7.3% | +9.3% | |
| Q1 2020 | +2.9% | +0.5% | +15.3% | |
| Q4 2019 | +4.5% | -16.4% | +0.4% | |
| Q3 2019 | -0.3% | +0.5% | +7.8% | |
| Q2 2019 | -5.2% | -10.6% | -10.2% | |
| Q1 2019 | +1.5% | -0.3% | -15.9% | |
| Q4 2018 | -1.9% | -4.9% | -15.2% | |
| Q3 2017 | +10.3% | +4.5% | -6.2% | |
| Q3 2018 | +10.3% | +4.5% | -6.2% | |
| Q2 2018 | -2.7% | -2.9% | -3.4% | |
| Q4 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro